Novo: We didn’t have the full grasp until Sunday
Novo Nordisk strongly disagrees with the Danish FSA’s decision to report the company to the police, saying it could not have informed the stock market any sooner than it did without causing “unreasonable uncertainty”.
by Stefan Singh Kailay
Although Novo Nordisk received the FDA’s decision that the agency would not be approving the company’s long-acting insulin analogue Tresiba on February 8, the Danish diabetes giant could not have informed the stock market any sooner than on February 10.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo reported to the police by Danish FSA
For abonnenter
